PPARA and myeloid sarcoma: In parallel with anti-inflammatory and remyelination effects, many studies have demonstrated protective effects of PPAR agonists against central players in the neurodegenerative process in MS and other disorders, including mitochondrial dysfunction, calcium dysregulation, glutamate toxicity and oxidative injury [175,177].